Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. - Wikidata - awgldk - TriplyDB

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

http://www.wikidata.org/entity/Q33803085

about

RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression Translational progress on tumor biomarkers CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer The Role of CC-Chemokines in the Regulation of Angiogenesis The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma Myeloid-derived cells are key targets of tumor immunotherapy High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time Macrophage plasticity and polarization: in vivo veritas RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.Identification of novel markers for the diagnosis of malignant pleural mesothelioma.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Roles of bone marrow cells in skeletal metastases: no longer bystanders The PCa Tumor Microenvironment.Monocyte chemotactic protein-1 promotes the proliferation and invasion of osteosarcoma cells and upregulates the expression of AKT Crosstalk between Tumor Cells and Macrophages in Stroma Renders Tumor Cells as the Primary Source of MCP-1/CCL2 in Lewis Lung Carcinoma.Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB Activity CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.Overcoming drug resistance and treating advanced prostate cancer Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.Ruguo key genes and tumor driving factors identification of bladder cancer based on the RNA-seq profile.Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines.Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.

P2860

Q24608385-4F7A88BA-4E89-4B0B-B165-7F100BA8273C Q26748194-87FF7B06-28B9-41CF-920F-52B11819258E Q26773413-DFF3778A-4D7C-44E5-801B-3900F40C19A8 Q26777676-EFD6B53A-947B-48C9-854D-34785CE30B0C Q26782520-93F47F36-4E39-434A-A8C4-1481361EEC27 Q28075965-C8062674-3F07-43CE-86AB-B4C56D390AE7 Q28077024-C7F5808C-251F-4E00-BAF2-33C4DDECE7D3 Q28241308-A803EE22-E519-4E15-AFC9-838579D4EC80 Q28387441-80A4F325-6FCC-497C-8B21-B3FDBE6B2D49 Q28388246-D98364F4-933A-4652-B961-E41BBA4543BF Q28536347-4BDA3081-504B-49A6-86BF-3D6F91C03DBD Q29547620-5CD8A9EC-09C4-4457-B627-76D4DE135C9C Q30423871-79CA691F-AD9A-4885-B847-B5007FB84170 Q33889144-BB8FC212-DC68-4717-8CD7-2F976FD0CA9A Q34289623-906F6358-437C-4E21-95BB-B7603080FD73 Q34326476-BC1BC44C-9B6F-4C1B-A56D-1F8FCBAB6D1A Q34619781-F0EE13D4-17C3-423D-AEA2-57619C25986D Q34760760-9F06EB19-2DC6-4C62-8DA6-CE2F36E8F6E1 Q35580479-961A91DC-9E5B-4B47-9B36-BBC193D9D769 Q35603122-0E1FC261-F88E-4439-812D-C7FAD3084194 Q35603143-B674C532-BE6A-448E-9DB7-B35365D35711 Q35628416-5876D5F7-B4F6-431D-BB21-C90E793DE40F Q35782923-A8035392-205D-4DB6-ADFA-76361C8D29DA Q35799695-CB425AE7-084C-4B4B-8709-23CB8143EF70 Q35843010-E2B414B4-03BB-4045-88A9-280602C1B460 Q35903509-C5695455-217E-46D8-9D90-4C66C8E5B23D Q35994680-C12BA21E-5301-411A-9C69-B08EDF1D7215 Q36184349-98F8DCD7-066C-474F-91C2-13C8A1227C8E Q36204706-E060A635-8181-4B48-9D6B-B09A8D37BB5F Q36241242-B4A2EA35-449C-4FD7-B174-D358CEAACBD3 Q36266500-CF6275E1-66AB-49AB-A2A5-DCBEA31C7CEE Q36278280-A853FA09-A8E2-4210-A549-901FF95AF604 Q36328812-B6333DC6-A148-4C2A-B372-9D257C55205C Q36363019-3A46D22C-AF56-4B79-9350-AE4F4EC1B503 Q36618810-ECCF840C-7365-4D4E-9A59-A469171EFE16 Q36638192-84A73264-F8D7-4EC3-A7B6-1FC754B4775C Q36891229-67470766-6FEB-432B-9864-3C1A9499E259 Q36913771-6C1E6DFA-FD50-42DF-AAD7-4219F3B2A70C Q37115310-0AE407BF-CD30-4C38-93B5-588962644C78 Q37236912-E727DC39-D04B-4E9E-BE56-366BC65F0141

P2860

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

http://www.wikidata.org/entity/Q33803085

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

@ast

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

@en

type

label

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

@ast

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

@en

prefLabel

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

@ast

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

@en

P1433

Q33803085-5BAD3DAA-D492-47DE-A285-D2583ED1BB0B

P1476

Q33803085-D4BC059F-4A7E-41C6-9EBB-FB258C3687AB

P2093

Q33803085-9A7AAFBB-B853-4A1C-BFDF-9655FE720D27

Q33803085-CF448BDD-5743-45D4-8BDC-E35D02BF9C78

P2860

Q33803085-0A68CB0C-8139-487F-9A8D-86663455C1BE

Q33803085-0B003B36-5F0A-422F-9B83-D08B376F81EB

Q33803085-0B3EB83E-FBF8-4563-89FA-6E4EC33A3432

Q33803085-0C29D918-B657-408C-A6C0-79B1D55E98D4

Q33803085-0FBE88D8-7B25-46BE-BBA1-1ED0A75305EC

Q33803085-1162681F-E2C1-496C-8B58-E64591029D9D

Q33803085-11E41AEC-8936-4778-8A80-DDF5618AE822

Q33803085-1223FE28-2803-4761-AA63-D04D584784AE

Q33803085-15702EE9-DA84-4122-88F7-40EF378B931C

Q33803085-16224713-B1FE-472A-806D-6187C83DFF79

P304

Q33803085-BEA6CA44-0BD4-43E5-B971-3C16A6EA10CF

P31

Q33803085-749B5D58-70BA-449C-AD45-436A2F78FFF8

P356

Q33803085-94CB8E7D-9131-4FE7-B36D-448A102F62BD

P407

Q33803085-31F3DE46-BE01-4631-84F4-6975F2DD09F4

P433

Q33803085-2527AB02-60CC-4D5B-93E2-0E07EA587ACB

P478

Q33803085-49A28D4C-E5DF-4768-8421-EE619750C9EF

P50

Q33803085-924BC331-C345-4E15-A323-A1B87974EB88

P577

Q33803085-57458C3E-880A-4790-9C58-7DF19958513D

P5875

Q33803085-9E128371-F665-42E1-9CFF-4FCCA119367A

P698

Q33803085-2248350B-5639-47FA-A02B-FA3B7F7344FF

P932

Q33803085-053ED6D6-8B89-4BD6-9148-54670F376E81

P356

P1433

Journal of the National Cancer Institute

P1476

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth

@en

P2093

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Yi Lu

http://www.w3.org/2001/XMLSchema#string

P2860

MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation

Cancer and the chemokine network

CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases

Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice

Cancer statistics, 2009

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer.

Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.

Role of endothelin-1 in osteoblastic bone metastases.

P304

522-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJQ044

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth J. Pienta

P577

2010-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239980159

http://www.w3.org/2001/XMLSchema#string

P698

20233997

http://www.w3.org/2001/XMLSchema#string

P932

2857800

http://www.w3.org/2001/XMLSchema#string